IASLC and LCRF Award Team Science Grant for Lung Cancer Research | Docwire News
The four-year grant is for $2.5 million and will fund a project titled, “Immune elimination of drug-tolerant persister cells in oncogene-driven lung cancer.”
The four-year grant is for $2.5 million and will fund a project titled, “Immune elimination of drug-tolerant persister cells in oncogene-driven lung cancer.”
Using an accelerated course of radiation therapy “does not increase complications” in patients who undergo breast reconstruction after a mastectomy.
A phase 2 study highlighted the potential of CD3-CD123 bispecific T-cell engaging antibody, vibecotamab, for treatment of high-risk myeloid neoplasms.
AbstractBackgroundN-terminal pro–B-type natriuretic peptides (NT-proBNPs) are guideline-recommended biomarkers for risk stratification in patients with heart failure. However, NT-proBNP levels are …
Essential Medical Tests for People in Their 50s and 60s with Dr. David Katz and Dr. Joel Kahn M.DDr. Khan shares his journey from a…
Resources for patients with cancer and care providers impacted by natural disasters and other catastrophic events.
AbstractThe burden of cardiovascular disease has declined in high-income countries in the past 3 decades but is growing in low- and middle-income countries due to…
Combined with the exporter-1 inhibitor, selinexor, ruxolitinib reduces spleen volume and reduces symptoms for participants with MF who did not respond well to JAK inhibitors.
Jason Shaw was in the best shape of his life when he had a heart attack that led to double bypass surgery.
Paul Saladino, known as the Carnivore MD, opened up about the negative side effects he experienced after following a restrictive carnivore diet for two years
Sign up for DocWire News eNewsletters to get the latest medical industry news and expert insights and to join an extensive community of health care…